NCT04250155

An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

A Phase Ia/Ib, Open-Label, Multicenter, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XmAb24306 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 195 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.

Conditions

• Solid Tumors

Interventions

Type	Name	Description
DRUG	XmAb24306	Participants will receive intravenous (IV) XmAb24306.
DRUG	Atezolizumab	Participants will receive IV XmAb24306 followed by IV atezolizumab
DRUG	XmAb24306	Participants will receive IV XmAb24306 followed by IV atezolizumab.

Timeline

• Start date: 2020-03-09
• Primary completion: 2026-06-15
• Completion: 2026-06-15
• First posted: 2020-01-31
• Last updated: 2026-02-24

Locations

25 sites across 9 countries: United States, Australia, Belgium, Brazil, Canada, Italy, Netherlands, South Korea, Spain

Regulatory

• FDA-regulated drug study